Introduction
============

Gastric cancer (GC, additionally termed stomach cancer) is derived from gastric mucosa ([@b1-mmr-17-05-6345]), 60% of which is induced by infection with the bacterium *Helicobacter pylori* ([@b2-mmr-17-05-6345]--[@b4-mmr-17-05-6345]). GC is characterized by several early signs (including heartburn, lack of appetite, nausea and upper abdominal pain) and certain later symptoms (including weight loss, dysphagia, vomiting and yellowing of the whites of the eyes and skin) ([@b5-mmr-17-05-6345]). If left untreated, GC may undergo diffusion transfer to other parts of the body, including the lungs, liver, lymph nodes and bones ([@b6-mmr-17-05-6345]). The 5-year survival rate of patients with GC is \<10% worldwide, and late discovery of illness may the worsen prognosis ([@b7-mmr-17-05-6345]). Globally, there were 950,000 new cases of GC and 723,000 mortalities in 2012 ([@b3-mmr-17-05-6345]). Therefore, early diagnosis, reasonable prognostic assessment, and timely and appropriate intervention are very important to improving the outcomes of GC.

The study of large numbers of prognostic markers may guide the clinical monitoring of patients at a high risk of relapse, and further treatment may be administered to improve the survival rate of patients with GC. Previous studies have demonstrated that astrocyte elevated gene 1 overexpression serves as a promising prognostic factor for GC, and targeted inhibition thereof may be a novel therapeutic strategy for the disease ([@b8-mmr-17-05-6345],[@b9-mmr-17-05-6345]). The expression of human epidermal growth factor receptor 2 can be used to predict sensitivity to trastuzumab-based chemotherapy and the overall survival of patients with advanced GC ([@b10-mmr-17-05-6345]). Adenine-thymine-rich interactive domain 1A is reported to be a potential prognostic marker and therapeutic target for GC ([@b11-mmr-17-05-6345],[@b12-mmr-17-05-6345]). The accuracies of these different biomarkers were not the same, thus more relevant prognostic factors are required. Okugawa *et al* ([@b13-mmr-17-05-6345]) reported that the brain-derived neutrophic factor (BDNF)/neurotrophic receptor tyrosine kinase 2 (TrkB) axis has an association with the prognosis of patients with GC, and the BDNF/TrkB pathway may serve an important role in the progression of GC. At present, the prognosis of GC primarily depends on such factors as serum markers and the clinical condition of a patient ([@b14-mmr-17-05-6345],[@b15-mmr-17-05-6345]). Combining multiple relevant genes and clinical factors may improve prognostic accuracy in GC.

Huang *et al* ([@b16-mmr-17-05-6345]) developed a novel computational model for breast cancer prognosis by combining the pathway deregulation score (PDS)-based pathifier algorithm, Cox proportional hazards regression and the L1-lasso penalization method to select promising targets for therapeutic intervention. Huang *et al* ([@b17-mmr-17-05-6345]) developed a novel computational method that uses personalized PDS with pathway-based metabolomics data analysis for breast cancer diagnosis. However, few studies have reported the value of pathway and clinical factor-based risk models for GC prognosis. The present study adopted similar methods, and aimed to investigate the prognostic ability of different risk prediction models based on the identified pathways and clinical factors associated with the prognosis of GC ([Fig. 1](#f1-mmr-17-05-6345){ref-type="fig"}).

Materials and methods
=====================

### Data source

Gene expression profiles of the GSE62254 dataset ([@b18-mmr-17-05-6345]) \[platform: GPL570 (HG-U133_Plus_2) Affymetrix (Thermo Fisher Scientific, Inc., Waltham, MA, USA) Human Genome U133 Plus 2.0 Array\] were obtained from the Gene Expression Omnibus (GEO; [www.ncbi.nlm.nih.gov/geo](www.ncbi.nlm.nih.gov/geo)) database. GSE62254 consisted of 300 GC tissue samples and served as a training set in the present study. These GC tissue samples were obtained from patients during gastrectomy procedures at Samsung Medical Centre, Seoul, Korea (2004--2007). Another mRNA-sequencing dataset for GC \[platform: Illumina, Inc. (San Diego, CA, USA) HiSeq 2000 RNA Sequencing\] was downloaded from The Cancer Genome Atlas (TCGA; [cancergenome.nih.gov](cancergenome.nih.gov)). This mRNA-sequencing dataset, containing 384 GC tissue samples, was taken as a validation set. The demographic and clinical characteristics of all samples in the training and validation set are presented in [Table I](#tI-mmr-17-05-6345){ref-type="table"}. In order to eliminate the technology bias in systematic measurement between the distinct datasets and platforms, these two datasets were independently standardized ([@b19-mmr-17-05-6345]).

### Data preprocessing and differentially expressed gene (DEG) screening

The background correction and data normalization of GSE62254 were performed using the oligo package ([www.bioconductor.org/packages/release/bioc/html/oligo.html](www.bioconductor.org/packages/release/bioc/html/oligo.html)) ([@b20-mmr-17-05-6345]) in R ([@b21-mmr-17-05-6345]). Based on the prognostic information, samples were divided into two groups: A poor prognosis group (samples from patients who survived for \<12 months and were deceased), and a good prognosis group (samples from patients who survived for \>60 months and were alive). Subsequently, the t-test ([127.0.0.1:26738/library/stats/html/t.test.html](127.0.0.1:26738/library/stats/html/t.test.html)) ([@b22-mmr-17-05-6345]) and the Wilcoxon test ([127.0.0.1:26738/library/stats/html/wilcox.test.html](127.0.0.1:26738/library/stats/html/wilcox.test.html)) ([@b23-mmr-17-05-6345]) in R were used for screening the genes that were significantly differentially expressed between the poor prognosis group and the good prognosis group. A false discovery rate \<0.05 and \|log fold change\| \>0.263 were considered to be the thresholds. Overlapping DEGs predicted by the t-test and Wilcoxon test were selected for further analysis.

### Identification of prognosis-associated genes and clinical factors

Prognosis-associated genes and clinical factors were selected using univariate and multivariate Cox regression analysis in the R survival package ([bioconductor.org/packages/survivalr](bioconductor.org/packages/survivalr)) ([@b24-mmr-17-05-6345]). A P-value \<0.05 was set as the cut-off criterion. The expression values of the prognosis-associated genes were extracted to perform bidirectional hierarchical clustering ([@b25-mmr-17-05-6345]) using the R heatmap package ([cran.r-project.org/web/packages/pheatmap/index.html](cran.r-project.org/web/packages/pheatmap/index.html)) ([@b26-mmr-17-05-6345]). The purpose of the hierarchical clustering analysis was to intuitively observe the differences in prognosis-associated gene expression between samples.

### Selection of prognosis-associated pathways

The Gene Set Enrichment Analysis (GSEA) database ([www.broadinstitute.org/gsea](www.broadinstitute.org/gsea)) ([@b27-mmr-17-05-6345]) is a microarray data analysis tool containing multiple functions and pathways. All the pathway annotation files of 217 Biocarta pathways and 186 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways in the GSEA database ([@b27-mmr-17-05-6345]) were downloaded and taken as reference pathways. Subsequently, the expression matrix of the prognosis-associated genes was converted into a pathway deregulation score (PDS) matrix of the relevant pathways using the principal components analysis algorithm in the R pathifier package ([bioconductor.org/packages/pathifier](bioconductor.org/packages/pathifier)) ([@b28-mmr-17-05-6345]). The optimal prognosis-associated pathways were screened subsequent to importing the PDS matrix using the Cox proportional hazards (Cox-PH) model in the R penalized package ([bioconductor.org/packages/penalized](bioconductor.org/packages/penalized)) ([@b29-mmr-17-05-6345]). The parameter 'lambda' was obtained upon performing 1,000 rounds of cross-validation likelihood (cvl) ([@b30-mmr-17-05-6345]) circular calculation.

### Construction and validation of risk prediction models

Based on the Cox-PH prognosis coefficients of the optimal prognosis-associated pathways, the pathway-based risk prediction model was constructed and the prognosis index (PI) score of each sample was calculated. According to the median of the PI scores, the samples in the training set were divided into high- and low-risk groups. The correlations between the risk prediction model and prognosis were estimated using the Kaplan-Meier (KM) method in the R survival package ([@b24-mmr-17-05-6345]). In addition, the risk prediction model was validated using the validation set.

Using the Cox-PH model in the R penalized package ([@b29-mmr-17-05-6345]), the optimal prognosis-associated genes were identified following importing of the gene expression matrix of the prognosis-associated genes. The gene-based risk prediction model was built and the PI score of each sample was calculated based on the Cox-PH prognosis coefficients of the optimal prognosis-associated genes. The median of the PI scores was considered the demarcation point, and the samples in the training set were additionally divided into high- and low-risk groups. Using KM survival curves, the correlations between the gene-based risk prediction model and prognosis were evaluated in the training set and the validation set. The predictive effects of the gene-based risk prediction model were compared to those of the pathway-based risk prediction model.

Using the Cox-PH model, the prognosis coefficients of the prognosis-associated clinical factors were determined, and a clinical factor-based risk prediction model was constructed. The PI scores of the samples were calculated. Subsequently, the samples in the training set were divided into high- and low-risk groups, with their median PI as the demarcation point. Using KM survival curves, the correlations between the clinical-factor-based risk prediction model and prognosis were assessed in the training set and the validation set. Furthermore, the predictive effects of the clinical factor-based risk prediction model were compared with those of the pathway-based risk prediction model.

When the Cox-PH prognosis coefficients of the optimal prognosis-associated pathways had been integrated with those of the prognosis-associated clinical factors, a risk prediction model was constructed based on clinical factors and pathways. The PI score of each sample was calculated, and their PI median was taken as the demarcation point to divide the samples in the training set into high- and low-risk groups. Additionally, the correlations between the risk prediction model and prognosis were estimated in the training set and the validation set. Finally, the predictive effects of the risk prediction model based on clinical factors and pathways were compared with those of the pathway-based risk prediction model.

Results
=======

### DEG screening

According to the prognostic information, 48 samples were classified into a poor prognosis group and 58 samples into a good prognosis group. A total of 617 DEGs and 671 DEGs were identified by the t-test and Wilcoxon test, respectively. The 382 overlapping DEGs (268 upregulated genes and 114 downregulated genes) were used for further analysis.

### Identification of the prognosis-associated genes and clinical factors

A total of 50 prognosis-associated genes ([Table II](#tII-mmr-17-05-6345){ref-type="table"}) and four prognosis-associated clinical factors \[including Pathologic_N, Pathologic_stage, mutL homolog 1 (MLH1) mutation, and recurrence\] ([Table III](#tIII-mmr-17-05-6345){ref-type="table"}) were screened based on the Cox regression analysis. Samples were divided into group 1 (including 173 GC samples) and group 2 (including 127 GC samples) according to the clustering analysis of prognosis-associated genes ([Fig. 2](#f2-mmr-17-05-6345){ref-type="fig"}). Moreover, significant differences were observed in the recurrence (P=1.29×10^−7^), Pathologic_N (P=1.77×10^−2^), Pathologic_stage (P=1.52×10^−3^), and MLH1 mutation (P=4.61×10^−2^) between the two groups. Group 1 had less recurrence, less lymphatic metastasis, lower tumor stage and more MLH1 mutations compared with group 2.

### Selection of prognosis-associated pathways

The expression matrix of the 50 prognosis-associated genes was converted into a PDS matrix, and 118 GC-associated pathways (including 26 Biocarta pathways and 92 KEGG pathways) were selected. Based on cvl circular calculation, the maximum value of cvl was −965.3297 (parameter 'lambda'=0.9361) ([Fig. 3](#f3-mmr-17-05-6345){ref-type="fig"}). Furthermore, 16 optimal prognosis-associated pathways including four Biocarta pathways (including the mitochondrial pathway) and 12 KEGG pathways \[including the tyrosine-protein kinase JAK (JAK)-signal transducer and activator of transcription (STAT) signaling pathway\] were obtained using the Cox-PH model with this parameter value ([Table III](#tIII-mmr-17-05-6345){ref-type="table"}). Meanwhile, 10 prognosis-associated genes \[caspase 7 (CASP7), myosin heavy chain 14 (MYH14), nicotinamide nucleotide adenylyltransferase 1 (NMNAT1), phosphoinositide-3-kinase regulatory subunit 3 (PIK3R3), peroxisome proliferator activated receptor γ (PPARG), tight junction protein 3 (TJP3), cation channel sperm associated auxiliary subunit β (CATSPERB), CDC43 effector protein 5 (CDC42EP5); collagen triple helix repeat containing 1 (CTHRC1), and dehydrogenase/reductase 11 (DHRS11)\] were involved in these 16 optimal prognosis-associated pathways.

The samples in GSE62254 were divided into group I (including 166 GC samples) and group II (including 134 GC samples), according to the clustering analysis of the PDS matrix of the 16 optimal prognosis-associated pathways ([Fig. 4](#f4-mmr-17-05-6345){ref-type="fig"}). Similarly, there were significant differences in recurrence (P=3.72×10^−5^), Pathologic_stage (P=9.77×10^−3^), and MLH1 mutation P=2.21×10^−2^) between these two groups. However, no notable difference was observed in Pathologic_N (P=2.49×10^−1^). Thus, group I had less recurrence, lower tumor stage and more MLH1 mutations compared with group II.

### Construction and validation of risk prediction models

The pathway-based risk prediction model was constructed and the PI score of each sample was obtained. Subsequently, the samples in the training set were divided into high- and low-risk groups ([Fig. 5](#f5-mmr-17-05-6345){ref-type="fig"}). Compared with the high-risk group, the low-risk group had a longer overall survival (OS) time (59.85 29.87 months vs. 41.36±29.65 months) and recurrence-free survival (RFS) time (44.65±28.99 months vs. 30.00±28.35 months) ([Fig. 5A and B](#f5-mmr-17-05-6345){ref-type="fig"}). The risk groups exhibited significant correlations with OS time (P=4.90×10^−7^; [Fig. 5A](#f5-mmr-17-05-6345){ref-type="fig"}) and RFS time (P=2.44×10^−7^; [Fig. 5B](#f5-mmr-17-05-6345){ref-type="fig"}). Furthermore, the area under the receiver operating characteristic (AUROC) values of OS and RFS were 0.8554 and 0.809, respectively ([Fig. 5E](#f5-mmr-17-05-6345){ref-type="fig"}). In the validation set, the low-risk group additionally had a longer OS time (23.41±22.06 vs. 13.56±7.46 months) and RFS time (2.33±22.14 vs. 13.06±7.52 months) compared with the high-risk group ([Fig. 5C and D](#f5-mmr-17-05-6345){ref-type="fig"}). The risk groups had significant correlations with OS time (P=1.15×10^−4^; [Fig. 5C](#f5-mmr-17-05-6345){ref-type="fig"}) and RFS time (P=2.62×10^−6^; [Fig. 5D](#f5-mmr-17-05-6345){ref-type="fig"}). Furthermore, the AUROC values of OS and RFS were 0.733 and 0.7559, respectively ([Fig. 5E](#f5-mmr-17-05-6345){ref-type="fig"}). These results indicated that the pathway-based risk prediction model was able to predict the consistent sample risk in the training set and the validation set.

Using the Cox-PH model, 10 optimal prognosis-associated genes were identified ([Table IV](#tIV-mmr-17-05-6345){ref-type="table"}). The gene-based risk prediction model was built, and the samples in training set were divided into high- and low-risk groups ([Fig. 6](#f6-mmr-17-05-6345){ref-type="fig"}). In the training set, the low-risk group had a longer OS time (58.20±31.09 vs. 42.99±29.96 months) and RFS time (38.31±30.70 vs. 29.13±28.35 months) compared with the high-risk group ([Fig. 6A and B](#f6-mmr-17-05-6345){ref-type="fig"}). The risk groups had significant correlations with OS time (P=3.06×10^−4^; [Fig. 6A](#f6-mmr-17-05-6345){ref-type="fig"}) and RFS time (P=3.62×10^−4^; [Fig. 6B](#f6-mmr-17-05-6345){ref-type="fig"}). The AUROC values of OS and RFS were 0.7966 and 0.7129, respectively ([Fig. 6E](#f6-mmr-17-05-6345){ref-type="fig"}). In the validation set, the low-risk group had a longer OS time (23.85±23.02 vs. 18.18±21.58 months) and RFS time (18.95±17.73 vs. 18.78±19.48 months) compared with the high-risk group ([Fig. 6C and D](#f6-mmr-17-05-6345){ref-type="fig"}). The risk groups had a significant correlation with OS time (P=4.88×10^−2^; [Fig. 6C](#f6-mmr-17-05-6345){ref-type="fig"}), although not with RFS time (P=8.50×10^−1^; [Fig. 6D](#f6-mmr-17-05-6345){ref-type="fig"}). The AUROC values of OS and RFS were 0.6969 and 0.6453, respectively ([Fig. 6E](#f6-mmr-17-05-6345){ref-type="fig"}). These findings suggested that the gene-based risk prediction model was not able to be completely verified in the validation set. In this way, the pathway-based risk prediction model outperformed the gene-based risk prediction model.

A clinical factor-based risk prediction model was constructed based on the four prognosis-associated clinical factors. In the training set, the low-risk group had a longer OS time (63.55±26.36 vs. 6.41±30.24 months) and RFS time (48.21±28.19 vs. 22.55±25.59 months) compared with the high-risk group ([Fig. 7A and B](#f7-mmr-17-05-6345){ref-type="fig"}). The risk groups had significant correlations with OS time (P=7.11×10^−15^; [Fig. 7A](#f7-mmr-17-05-6345){ref-type="fig"}) and RFS time (P=1.11×10^−16^; [Fig. 7B](#f7-mmr-17-05-6345){ref-type="fig"}). In the validation set, the low-risk group had a longer OS time (20.06±16.33 vs. 18.66±17.75 months) and RFS time (22.52±24.23 vs. 16.93±10.74 months) compared with the high-risk group ([Fig. 7C and D](#f7-mmr-17-05-6345){ref-type="fig"}). The risk group had significant correlations with OS time (P=1.51×10^−2^; [Fig; 7C](#f7-mmr-17-05-6345){ref-type="fig"}) and RFS time (P=1.56×10^−12^; [Fig. 7D](#f7-mmr-17-05-6345){ref-type="fig"}).

Finally, the comprehensive risk prediction model based on the optimal prognosis-associated pathways and the prognosis-associated clinical factors was constructed. In the training set, the low-risk group had longer OS time (64.34±25.33 vs. 36.76±30.09 months) and RFS time (50.33±26.98 vs. 24.05±25.81 months) compared with the high-risk group ([Fig. 8A and B](#f8-mmr-17-05-6345){ref-type="fig"}). The risk groups had significant correlations with OS time (P=1.18×10^−14^; [Fig. 8A](#f8-mmr-17-05-6345){ref-type="fig"}) and RFS time (P=2.00×10^−16^; [Fig. 8B](#f8-mmr-17-05-6345){ref-type="fig"}). In the validation set, the low risk group had a longer OS time (21.37±16.41 vs. 18.35±17.68 months) and RFS time (22.01±20.32 vs. 19.35±17.73 months) compared with the high-risk group ([Fig. 8C and D](#f8-mmr-17-05-6345){ref-type="fig"}). The risk groups had significant correlations with OS time (P=2.28×10^−3^; [Fig. 8C](#f8-mmr-17-05-6345){ref-type="fig"}) and RFS time (P=7.75×10^−11^; [Fig. 8D](#f8-mmr-17-05-6345){ref-type="fig"}). The pathway- and clinical-factor-based risk prediction model may have better prognostic accuracy, since it had better robustness and more significant P-values.

Discussion
==========

In the present study, the gene expression profiles of the GSE62254 downloaded from GEO served as the training set and another mRNA-sequencing dataset obtained from TCGA served as the validation set. Although huge and heterogeneous collections frequently dilute specific results and favor secondary effects, these two datasets were independently standardized to partially eliminate the technology bias in systematic measurement. The 382 overlapping DEGs were screened for further analysis, including 268 upregulated genes and 114 downregulated genes. In the present study, 50 prognosis-associated genes and four prognosis-associated clinical factors (including Pathologic_N, Pathologic_stage, MLH1 mutation and recurrence) were identified. Based on the prognosis-associated genes, the samples in GSE62254 were divided into group 1 and group 2. The present results demonstrated that group 1 had less recurrence, less lymphatic metastasis, lower tumor stage and more MLH1 mutations compared with group 2. Using the Cox-PH model, 16 optimal prognosis-associated pathways (including the mitochondrial pathway and the JAK-STAT signaling pathway, involving CASP7, MYH14, NMNAT1, PIK3R3, PPARG, TJP3, CATSPERB, CDC42EP5, CTHRC1 and DHRS11) were selected. Similarly, the samples were divided into group I and II based on the 16 optimal prognosis-associated pathways. Group I was observed to have less recurrence, lower tumor stage and more MLH1 mutations compared with group II.

The expression levels of CASP2, CASP6 and CASP7 are decreased in GC cells, which may be associated with the pathogenesis of GC ([@b31-mmr-17-05-6345]). CASP7 in the apoptosis pathway functions as a critical mediator and executor, and its potential functional variants may increase the risk of GC ([@b32-mmr-17-05-6345]). Upregulated PIK3R3 was demonstrated to contribute to cell cycle progression and cell proliferation, indicating that PIK3R3 may be a promising target for the treatment of GC ([@b33-mmr-17-05-6345]). The phosphatidylinositol 3-kinase/RAC-α serine/threonine-protein kinase/serine/threonine-protein kinase mTOR signaling pathway is considered to have been implicated in the mechanisms of GC and contributes to the identification of potential therapeutic targets for the disease ([@b34-mmr-17-05-6345],[@b35-mmr-17-05-6345]). Optimal prognosis-associated pathways may serve important roles in the pathogenesis of GC via CASP7 and PIK3R3.

PPARG, plasma gastrin and proinflammatory cytokines have been reported to be correlated with GC development, and PPARG agonists have the potential to be used for cancer therapy ([@b36-mmr-17-05-6345],[@b37-mmr-17-05-6345]). PPARG may suppress the proliferation and migration of GC cells by inhibiting enabled homolog and telomerase reverse transcriptase expression, thus PPARG may serve as a therapeutic target for GC ([@b38-mmr-17-05-6345]). CTHRC1 expression may be regulated by transforming growth factor-β1 and promoter demethylation, and high levels of CTHRC1 expression promote the invasion and metastasis of tumor cells during gastric carcinogenesis ([@b39-mmr-17-05-6345],[@b40-mmr-17-05-6345]). The upregulated expression of CTHRC1 may independently predict the disease-free survival and overall survival of patients with GC, demonstrating that the high levels of expression of CTHRC1 are associated with the progression and prognosis of GC ([@b41-mmr-17-05-6345]). These suggested that the optimal prognosis-associated pathways may be associated with the development and progression of GC via PPARG and CTHRC1.

Via a mitochondrial pathway, juglone has been reported to be able to induce the apoptosis of GC SGC-7901 cells ([@b42-mmr-17-05-6345]). *H. pylori* infection leads to activation of CASP3 and CASP9, and to apoptosis in GC cells, and the mitochondrial pathway may be important to *H. pylori-*induced apoptosis ([@b43-mmr-17-05-6345]). CyclinB1 expression may be downregulated by fucoxanthin in human GC MGC-803 cells, in which the JAK-STAT signaling pathway serves an important role ([@b44-mmr-17-05-6345]). The mitochondrial pathway and JAK-STAT signaling pathway may be involved in the mechanisms of GC. A previous study demonstrated that MLH1 methylation status and CpG island methylator phenotype may be suitable prognostic biomarkers for patients with GC ([@b45-mmr-17-05-6345]). Checkpoint with forkhead and ring finger domains methylation may be considered to be a docetaxel-sensitive marker, and MLH1 methylation is correlated with oxaliplatin resistance in patients with GC ([@b46-mmr-17-05-6345]). These findings indicated that MLH1 mutation might serve as a prognostic biomarker for GC. Taken together, the prognosis-associated genes involved in the optimal-prognosis-associated pathways in the present prognosis model are promising targets for therapeutic intervention.

In the present study, the pathway-based risk prediction model and clinical-factor-based risk prediction model outperformed the gene-based risk prediction model. Although the gene-based risk prediction model had acceptable results in the training set (OS: P=3.06×10^−4^, AUC = 0.7966; RFS: P=3.62×10^−4^, AUC=0.7129), this model was not able to be completely verified in the validation set (OS: P=4.88×10^−2^, AUC =0.6969; RFS: P\>0.05). The results of the pathway-based risk prediction model in the training set (OS: P=4.90×10^−7^, AUC = 0.8554; RFS: P=2.44×10^−7^, AUC = 0.809) and in the validation set (OS: P=1.15×10^−4^, AUC = 0.733; RFS: P=2.62×10^−6^, AUC = 0.7559) indicated that this model had good performance. Furthermore, the clinical factor-based risk prediction model (training set, OS: P=7.11×10^−15^, RFS: P=1.11×10^−16^; validation set, OS: P=1.51×10^−2^, RFS: P=1.56×10^−12^) improved the P-values of prognosis prediction, rendering them higher compared with those of the pathway-based risk prediction model. The comprehensive risk prediction model, based on the optimal prognosis-associated pathways and the prognosis-associated clinical factors, yielded good predictive results (training set, OS: P=1.18×10^−14^, RFS: P=2.00×10^−16^; validation set, OS: P=2.28×10^−3^, RFS: P=7.75×10^−11^). In this way, the pathway and clinical factor-based risk prediction model may be suitable for predicting the prognosis of patients with GC.

In conclusion, 50 prognosis-associated genes, 16 optimal prognosis-associated pathways and four prognosis-associated clinical factors were identified. The pathway and clinical factor-based risk prediction model might be suitable for predicting the prognosis of GC patients. The prognosis-associated genes involved in the optimal prognosis-associated pathways in the present prognostic model (including CASP7, PIK3R3, PPARG, CTHRC1 and MLH1) are promising targets for therapeutic intervention. However, further study is required to validate the prognostic prediction model, based on the optimal prognosis-associated pathways and the prognosis-associated clinical factors, in an independent patient cohort with gastric cancer.
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![KM survival curves based on the clinical factor-based risk prediction model. (A) The KM survival curve illustrating the OS time in the training set; (B) the KM survival curve illustrating the RFS time in the training set; (C) the KM survival curve illustrating the OS time in the validation set; (D) the KM survival curve illustrating the RFS time in the validation set. Blue and green represent low- and high-risk groups, respectively. KM, Kaplan-Meier; OS, overall survival; RFS, recurrence-free survival.](MMR-17-05-6345-g06){#f7-mmr-17-05-6345}

![KM survival curves based on the pathway and clinical factor-based risk prediction model. (A) KM survival curve illustrating the OS time in the training set; (B) the KM survival curve illustrating the RFS time in the training set; (C) the KM survival curve illustrating the OS time in the validation set; (D) the KM survival curve illustrating the RFS time in the validation set. Blue and green represent low- and high-risk groups, respectively. KM, Kaplan-Meier; OS, overall survival; RFS, recurrence-free survival.](MMR-17-05-6345-g07){#f8-mmr-17-05-6345}

###### 

Clinical characteristics of patients in the training set (GSE62254) and the validation set (TCGA dataset).

  Clinical characteristics                                    GSE62254 (n=300)   TCGA (n=384)
  ----------------------------------------------------------- ------------------ ------------------
  Age, years (mean ± standard deviation)                      61.94±11.36        65.15±10.61
  Sex, male/female                                            199/101            243/133/8
  Pathologic_M, M0/M1/-                                       273/27             341/19/24
  Pathologic_N, N0/N1/N2/N3                                   38/131/80/51       118/100/77/16
  Pathologic_T, T1/T2/T3/T4/-                                 2/186/91/21        20/74/172/107/11
  Pathologic_stage, I/II/III/IV/-                             30/96/95/77/2      51/116/174/31/12
  Pathology type, diffuse/intestinal/mixed/-                  134/146/17/3       --
  MLH1 mutation, yes/no/-                                     234/64/2           18/366
  EBV infection, yes/no/-                                     18/257/25          --
  Recurrence, yes/no/-                                        125/157/18         78/260/46
  Venous invasion, yes/no/-                                   44/129/127         --
  Lymphatic lymphovascular invasion, yes/no/-                 205/73/22          --
  Subtypes, MSS-TP53^‒^/MSS-TP53^+^/MSI-EMT/-                 107/79/68/46       --
  Mortality, deceased/alive/-                                 135/148//17        122/238/24
  Disease-free survival, months (mean ± standard deviation)   33.72±29.82        15.84±17.05
  Overall survival time, months (mean ± standard deviation)   50.59±31.42        16.17±16.96

TCGA, The Cancer Genome Atlas; MLH1, mutL homolog 1; EBV, Epstein-Barr virus; MSS-TP53‒, Microsatellite stable-tumor protein 53-inactive; MSS-TP53+, microsatellite stable-tumor protein 53-active; MSI-EMT, microsatellite instable-epithelial to mesenchymal transition.

###### 

Prognosis-associated genes (n=50) identified by the Cox regression analysis.

  Gene        Univariate cox P-value   Multivariate cox P-value
  ----------- ------------------------ --------------------------
  TTC38       4.70×10^‒02^             3.62×10^‒06^
  DNAJC16     1.30×10^‒04^             1.87×10^‒05^
  RAB11FIP4   3.40×10^‒06^             1.09×10^‒04^
  CDC42EP5    1.00×10^‒08^             5.42×10^‒04^
  MYH14       3.20×10^‒06^             6.85×10^‒04^
  LRRC31      3.00×10^‒02^             7.77×10^‒04^
  SIAE        2.90×10^‒06^             1.53×10^‒03^
  SP6         1.50×10^‒03^             1.76×10^‒03^
  PKD2        1.90×10^‒06^             2.03×10^‒03^
  UBE2E2      1.70×10^‒04^             2.13×10^‒03^
  TNFRSF11A   2.20×10^‒09^             2.41×10^‒03^
  RBPMS2      4.90×10^‒14^             2.42×10^‒03^
  SLC45A3     3.30×10^‒02^             3.76×10^‒03^
  ANKRD6      4.50×10^‒06^             3.83×10^‒03^
  EGR2        3.60×10^‒02^             3.89×10^‒03^
  TMPRSS4     4.80×10^‒03^             4.44×10^‒03^
  TTC7B       1.40×10^‒04^             4.57×10^‒03^
  INHBB       1.10×10^‒06^             4.80×10^‒03^
  LYPD1       7.70×10^‒05^             5.76×10^‒03^
  C1orf216    1.00×10^‒03^             5.87×10^‒03^
  CTHRC1      3.20×10^‒02^             6.03×10^‒03^
  DHRS11      1.10×10^‒02^             6.35×10^‒03^
  PBX3        4.40×10^‒07^             6.61×10^‒03^
  PIK3R3      2.00×10^‒03^             7.17×10^‒03^
  PCSK7       4.50×10^‒06^             8.36×10^‒03^
  DFNA5       5.50×10^‒06^             9.16×10^‒03^
  CATSPERB    5.30×10^‒03^             9.93×10^‒03^
  PPARG       6.20×10^‒05^             1.06×10^‒02^
  SLC44A3     4.60×10^‒03^             1.38×10^‒02^
  STAMBPL1    2.20×10^‒04^             1.74×10^‒02^
  ALPK1       6.80×10^‒07^             1.76×10^‒02^
  SERAC1      5.70×10^‒05^             1.78×10v
  BCAR3       1.60×10^‒02^             2.02×10^‒02^
  TJP3        1.90×10^‒03^             2.20×10^‒02^
  TMEM144     3.70×10^‒06^             2.22×10^‒02^
  STARD5      8.40×10^‒04^             2.33×10^‒02^
  BPNT1       8.20×10^‒05^             2.36×10^‒02^
  CCDC92      9.00×10^‒07^             2.52×10^‒02^
  RNF170      2.60×10^‒03^             2.58×10^‒02^
  FBXL6       1.20×10^‒03^             2.83×10^‒02^
  CASP7       6.70×10^‒11^             3.01×10^‒02^
  RILPL1      1.30×10^‒07^             3.17×10^‒02^
  KLHDC8B     1.80×10^‒07^             3.34×10^‒02^
  HOXC4       3.40×10^‒04^             3.62×10^‒02^
  FAM83E      1.10×10^‒02^             3.71×10^‒02^
  MFSD9       2.20×10^‒04^             3.98×10^‒02^
  ZNRF2       5.10×10^‒07^             4.01×10^‒02^
  NMNAT1      2.50×10^‒08^             4.18×10^‒02^
  BTNL3       5.40×10^‒03^             4.65×10^‒02^
  F12         5.30×10^‒05^             4.96×10^‒02^

###### 

Prognosis-associated clinical factors and the optimal prognosis-associated pathways in the Cox-PH model.

  Feature           Description                                      Coefficient   Hazard ratio   P-value (univariate Cox-PH)
  ----------------- ------------------------------------------------ ------------- -------------- -----------------------------
  Pathway           BIOCARTA_DEATH_PATHWAY                           0.115         1.966          8.73×10^‒06^
                    BIOCARTA_DNAFRAGMENT_PATHWAY                     0.188         1.716          1.51×10^‒05^
                    BIOCARTA_MITOCHONDRIA_PATHWAY                    0.614         3.156          4.62×10^‒06^
                    BIOCARTA_PARKIN_PATHWAY                          0.285         1.737          2.06×10^‒05^
                    KEGG_CHRONIC_MYELOID_LEUKEMIA                    −0.029        0.398          1.36×10^‒04^
                    KEGG_ENDOMETRIAL_CANCER                          −0.299        0.260          1.02×10^‒02^
                    KEGG_ERBB_SIGNALING_PATHWAY                      −0.180        0.849          4.94×10^‒03^
                    KEGG_FC_EPSILON_RI_SIGNALING_PATHWAY             −0.096        0.619          6.39×10^‒03^
                    KEGG_FOCAL_ADHESION                              −0.562        0.178          1.54×10^‒02^
                    KEGG_JAK_STAT_SIGNALING_PATHWAY                  −0.256        0.374          4.50×10^‒06^
                    KEGG_LEUKOCYTE_TRANSENDOTHELIAL_MIGRATION        0.344         1.031          2.22×10^‒05^
                    KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY   0.024         1.062          1.33×10^‒06^
                    KEGG_NICOTINATE_AND_NICOTINAMIDE_METABOLISM      0.359         1.569          8.86×10^‒05^
                    KEGG_PATHWAYS_IN_CANCER                          −0.143        0.332          1.52×10^‒06^
                    KEGG_PPAR_SIGNALING_PATHWAY                      −0.135        0.835          2.07×10^‒04^
                    KEGG_TIGHT_JUNCTION                              0.959         1.353          2.50×10^‒13^
  Clinical factor   Recurrence                                       2.074         2.574          2.00×10^‒16^
                    Pathologic_N                                     0.165         1.956          3.97×10^‒13^
                    Pathologic_stage                                 0.233         2.215          6.66×10^‒16^
                    MLH1 mutation                                    0.024         2.027          2.69×10^‒03^

Cox-PH, Cox-proportional hazards; KEGG, Kyoto Encyclopedia of Genes and Genomes; MLH1, mutL homolog 1.

###### 

Optimal prognosis-associated genes (n=10) identified by the Cox-PH model.

  Gene        Coefficient   Hazard ratio   P-value (univariate Cox-PH)
  ----------- ------------- -------------- -----------------------------
  CATSPERB    −0.935        0.970          1.09×10^‒04^
  CDC42EP5    0.176         0.551          5.42×10^‒04^
  CTHRC1      −0.457        0.761          2.13×10^‒03^
  DHRS11      −0.160        1.232          2.42×10^‒03^
  EGR2        −0.196        0.283          3.89×10^‒03^
  INHBB       0.127         2.043          4.80×10^‒03^
  RAB11FIP4   −0.224        1.058          6.03×10^‒03^
  RBPMS2      0.322         3.517          6.35×10^‒03^
  STAMBPL1    −0.244        0.274          9.93×10^‒03^
  UBE2E2      0.303         4.114          1.74×10^‒02^

Cox-PH, Cox-proportional hazards; CATSPERB, cation channel sperm associated auxiliary subunit β; CDC42EP5, CDC42 effector protein 5; CTHRC1, collagen triple helix repeat containing 1; DHRS11, dehydrogenase/reductase 11; EGR2, early growth response 2; INHBB, inhibin β B subunit; RAB11FIP4, RAB11 family interacting protein 4; RBPMS2, RNA binding protein mRNA processing factor 2; STAMBPL1, STAM binding protein-like 1; UBE2E2, ubiquitin conjugating enzyme E2 E2.
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